IMDX — Insight Molecular Diagnostics Inc.

IMDX Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash and equivalents at the end of Q3 2025 stood at $20 million, with no debt.
• Lab services revenue was as expected, with a sequentially flat outlook for Q4.
• Q3 cash burn was below the target of $6 million, attributed to some expenses shifting to Q4; Q4 cash burn is expected to increase slightly due to FDA submission and clinical trial costs.
• The company plans to transition to discussing adjusted EBITDA and non-GAAP net income in future reports to provide clearer profitability metrics.

2. Strategic Updates and Business Highlights:

• IMDX is preparing for the FDA submission of GraftAssure DX by the end of 2025, with a focus on in-house testing for transplant patients.
• A pilot program has optimized the assay's workflow, reducing steps from two to one, enhancing turnaround time and usability.
• Positive feedback from clinical trials and studies indicates strong performance compared to legacy technologies, with ongoing studies expected to yield more data in 2026.
• The company is launching a registry program to familiarize clinicians with their testing technology and gather real-world data.
• IMDX is shifting from a development-only stage to a commercial organization, anticipating significant growth opportunities in the transplant diagnostics market.

3. Forward Guidance and Outlook:

• IMDX maintains a target for a mid-2026 launch of GraftAssure DX, contingent on FDA approval.
• The company expects to validate heart and lung assays in 2026 and 2027, leveraging existing analytical work to streamline regulatory submissions.
• The total addressable market (TAM) for kitted transplant testing is estimated to exceed $1 billion, driven by increased transplant volumes and potential guideline adoptions.

4. Bad News, Challenges, or Points of Concern:

• The ongoing U.S. government shutdown poses risks to the FDA review process, potentially delaying timelines for submission and approval.
• The company has not received responses to outstanding FDA questions due to the shutdown, which could impact preparation for the submission.
• There is a need for head-to-head testing to facilitate clinician adoption of GraftAssure DX, which may slow initial uptake.
• Concerns about reimbursement models and the impact of draft LCDs on testing frequency and revenue potential were raised.

5. Notable Q&A Insights:

• Analysts inquired about the potential impact of the LCD from Palmetto GBA on market opportunities, with management expressing hope for favorable outcomes that would support increased testing frequency.
• The company emphasized the importance of generating clinical data to support adoption and highlighted the positive feedback from clinicians regarding the assay's predictive value.
• Management acknowledged the challenges of sample enrollment in clinical trials but expressed confidence in meeting submission requirements by year-end.
• The discussion underscored the importance of strategic partnerships and market access initiatives to drive growth and engagement with transplant centers.

Overall, IMDX is positioning itself for significant growth in the transplant diagnostics market, despite facing regulatory and operational challenges. The upcoming FDA submission and the transition to a commercial focus are pivotal for the company's future.